{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "0181735cab6e7a5fe35531822ffb8a9c",
    "title": "Topline Dolce Vitae",
    "source_uri": "2025-08-28/Agilent Topline Dolce VitaAgilent Topline Dolce Vita_2025-08-28",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T01:26:18.468798",
      "extracted_at": "2025-10-26T01:26:18.468809"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 15,
        "successful_pages": 15,
        "date": "2025-08-28",
        "publication": "2025-08-28",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 9,
          "removed_paragraphs": 39,
          "reduction_ratio": 0.5038622282210983
        },
        "input_relative_path": "2025-08-28"
      }
    }
  },
  "passages": [
    {
      "passage_id": "0f6a234a42fe4e9a",
      "text": "Strong topline beat driven by NASD, LC/MS and the start of a CAM- driven GC replacement cycle was overshadowed by weak margins. Margin weakness will give bears plenty to poke at, especially when it comes to how that affects '26 EPS growth...",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "4e67d4be561c462b",
      "text": "...Overall a solid quarter but margins will likely be a show- me story in the next few quarters and it may limit upside to the shares in the NT.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "84d48af7aaf6c95c",
      "text": "The setup for Agilent coming into the Q was skewed positive, with a topline beat expected, following strong prints from the rest of the group. In addition, Agilent's exposure to stronger markets, NASD read- throughs from ALNY drug volumes and approvals, and the fact that they are earlier in the LC/MS replacement cycle than WAT contributed to the narrative. Even then, topline exceeded those heightened expectations, especially in Crosslab and AMG. Notably, the CAM end market was strong (+10%) as a GC instrument replacement cycle seemed to begin/meaningfully accelerate and semi fab build- outs continued. This replacement cycle for GC- MS (~20% of the biz) has a longer conversion rate, so we can expect this to be a more drawn out TW for the company vs. the 5- 7 year cycle we see now for LC- MS. The GC- MS replacement cycle is likely being treated as a one- timer by investors following the print since it did not appear to be well understood going into the Q and there was little commentary on the durability of this cycle, so it will likely be a show me- story in the next few Qs. On LC/MS, ProIQ and Infinity 3 innovation continue to drive the replacement cycle with LDD growth in both LC and LC/MS.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ee0b4dc4e148a375",
      "text": "Bears, however, may point to margins coming in 140bps below ST and down 230bps yoy as potentially jeopardizing 2026 EPS growth should margin HWs persist despite the strong topline and underlying end- market strength. Digging deeper into the margin dynamics, 1/3 of the margin HW in the Q came from tariff- related costs that were \\(\\sim\\) 355M, 510M greater than the \\(\\) 25M\\(guide going into the quarter due to stronger revenues, 1/3 came from variable pay increases due to performance another 1/3 coming from incremental commercial investments. We understand that tariff and additional commercial investments were unforeseen by mgmt. going into the Q in fact we see higher tariffs due to revenue outperformance as a positive and additional investment in the commercial organization as a vote of confidence in the durability of strength in the end markets. There is also push back on 4Q margins that mgmt expect to increase 230bps sequentially through additional Ignite cost actions, fx settling down, but primarily on volume leverage on the CDMO side of the business. Ultimately, margins will likely be a show- me story given the number of moving pieces and how underappreciated the NASD/CDMO margin dynamic is.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "da06deceb008e9a4",
      "text": "Please see analyst certifications and important disclosures beginning on page 9. Completed: 28- Aug- 25, 10:52 GMT Released: 28- Aug- 25, 10:56 GMT Restricted - External",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "e1cc95625068ac4d",
      "text": "U.S. Life Science & Diagnostic Tools",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b33822abaa03fa57",
      "text": "Potential Upside/Downside +5.3% Source: Bloomberg, Barclays Research",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b1e6bfda26312a9b",
      "text": "Market Cap (USD mn) 33715 Shares Outstanding (mn) 284.06 Free Float (%) 99.61 52 Wk Avg Daily Volume (mn) 1.8 Dividend Yield (%) 0.84 Return on Equity TTM (%) 18.88 Current BVPS (USD) 21.61 Source: Bloomberg",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5e701b8c0d6a6794",
      "text": "Price Performance Exchange- NYSE 52 Week range USD 153.84- 96.43",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "06364b3c764f01f7",
      "text": "Source: IDC Link to Barclays Live for interactive charting",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2d57e2a739ea95a1",
      "text": "On this, we believe margin dynamics are misunderstood on the NASD/CDMO business. The current understanding amongst investors appears to be that topline acceleration from outsized NASD growth will come at the expense of corporate margins. And while mgmt. expects this business to be dilutive to GMs next Q, it is actually expected to be accretive to overall OMs. The investor narrative has now become whether peak margin days are behind the company given the shifting mix. We plan to do more work around these dynamics given that this seems to be an underappreciated part of the story.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "76b7c3e9616b8023",
      "text": "To us, the overall print was impressive as the Pharma and CAM end markets showed strength, and innovation drove topline growth. Margin uncertainty will likely limit upside and may be a show- me story going into 4Q and '26. We don't have a clear line of sight for margins to come in- line with consensus expectations. Hence, we remain on the sidelines and leave our PT unchanged at \\(125 which is based on 21x our '26 EPS estimate of\\) 6.06 vs. 21x on our \\(6.01 estimate prior.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "0c64c5ea89332d45",
      "text": "3Q Results 6  End- Markets 6  Guidance 7  End- Guidance Notes 7  ÔÅ∂ 4Q Guidance 7  Key Takes from the Call 7",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "eceebbb8520fa818",
      "text": "A:Quarterly and Annual EPS (USD)",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "221097cc49d96281",
      "text": "202420252026Change y/yFY OctActualOldNewConsOldNewCons20252026Q11.29A1.31A1.31A1.31AN/A1.46E1.43E2%11%Q21.22A1.31A1.31A1.31AN/A1.46E1.43E7%11%Q31.32A1.37E1.37A1.37EN/A1.51E1.51E4%10%Q41.46A1.59E1.58E1.60EN/A1.64E1.70E8%4%Year5.28A5.58E5.57E5.58E6.01E6.06E6.05E5%9%P/E22.521.319.6",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "94d717148951c7cd",
      "text": "Consensus numbers are from Bloomberg received on 27-Aug-2025; 12:50 GMT Source: Barclays Research",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "7b22eccba9deacfd",
      "text": "U.S. Life Science &amp; Diagnostic ToolsAgilent (A)Income statement (US$mn)2024A2025E2026E2027ECAGREQUAL WEIGHTRevenue6,5106,9187,2587,6655.6%Price Target USD 118.69EBITDA (adj)1,8751,9612,0802,2696.6%Price Target USD 125.00EBIT (adj)1,7201,7801,9352,1157.1%Why EQUAL WEIGHT?Pre-tax income (adj)1,7551,8061,9352,0956.1%We expect Agilent to maintain its HSD topline/LDD EPS compoundingNet income (adj)1,5381,5891,7031,8446.2%algo over time by capturing secular TWs. We remain on the sidelinesEPS (adj) (US$)5.285.576.066.597.7%given elevated valuations as the instrumentation recovery is underway, but we remain cautious around China, continued momentum in capex spend, A&amp;amp;G markets, and geopolitics.Diluted shares (mn)291284281280-1.3%DPS (US$)0.941.001.041.084.6%Margin and return data2024A2025E2026E2027EAverageGross margin (%)55.754.054.655.554.9EBITDA (adj) margin (%)26.425.726.727.626.6EBIT (adj) margin (%)26.425.726.727.626.6Pre-tax (adj) margin (%)27.026.126.727.326.8Net (adj) margin (%)23.623.023.524.123.5ROIC (%)19.418.118.820.419.2ROA (%)13.012.613.113.713.1ROE (%)26.124.023.122.323.9Balance sheet and cash flow (US$mn)2024A2025E2026E2027ECAGRTangible fixed assets1,7782,0462,2642,37910.2%Downside is driven by Agilent catching more secular tailwinds than anticipated and the NASD business outperforming current projections.Intangible fixed assets5,0245,8395,6945,5403.3%Cash and equivalents1,3291,1941,3741,6717.9%Total assets11,84612,60813,00513,4314.3%Short and long-term debt3,3453,3453,0462,450-9.9%Other long-term liabilities708692653690-0.9%Total liabilities5,9485,9885,6195,157-4.6%Net debt/(funds)2,0162,1511,672779-27.2%Shareholders' equity5,8986,6207,3858,27511.9%Change in working capital8359-128-16N/ACash flow from operations1,7512,0001,6371,9653.9%Capital expenditure-378-450-363-268N/AFree cash flow1,3731,5501,2751,6967.3%Valuation and leverage metrics2024A2025E2026E2027EAverageNet debt/EBITDA (adj) (x)1.11.10.80.30.8P/E (adj) (x)22.521.319.618.020.4EV/sales (x)5.55.24.94.55.0EV/EBITDA (adj) (x)19.118.317.115.317.4EV/EBIT (adj) (x)20.820.218.316.418.9FCF yield (%)3.84.33.64.94.2Dividend yield (%)0.80.80.90.90.9Selected operating metrics2024A2025E2026E2027EAverageSG&A/sales (%)22.321.821.721.621.9SG&A growth (%)-1.63.94.15.32.9",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "c30178f8cb3655a6",
      "text": "Source: Company data, Bloomberg, Barclays Research",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "6e0bdc3ccdf161c2",
      "text": "FIGURE 1.3Q'25 Variance \\(S\\) in millions, except earnings per share",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "51b92a9e30918841",
      "text": "Quarter VarianceACTION3Q&#x27;25 ActualStreet (Bloomberg) 3Q&#x27;25%ŒîBarclays ResearchTotal RevenueBEAT$1,738$1,6664.3%$1,664CoreBEAT6.1%2.9%320 bps2.9%Adj. OMMISSED25.1%26.6%(141 bps)26.3%Adj. EPSIN-LINE$1.37$1.37$0.00$1.37",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "3b23461a8885cc03",
      "text": "Source: Company Reports, Bloomberg, Barclays Research",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "3252c3a0764c4c3f",
      "text": "FIGURE 2.3Q'25 Segment Variance",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "6d3ac3819015f65c",
      "text": "Segment VarianceACTION3Q&#x27;25 ActualST (Bloomberg) 3Q&#x27;25%ŒîLDGRevenueBEAT$670$6414.5%Core*BEAT7.0%3.0%400 bpsOMMISSED17.6%21.5%(386 bps)ACGRevenueBEAT$744$7173.7%CoreBEAT5.0%2.7%235 bpsOMBEAT33.3%32.4%91 bpsAMGRevenueBEAT$324$3085.3%Core*BEAT5.0%1.0%400 bpsOMMISSED21.8%23.5%(174 bps)",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "9c0e99279c2141f6",
      "text": "LDG & AMG core growth variance reflects Barclays estimates Source: Company Reports, Bloomberg, Barclays Research",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "83d5c5f05444c08c",
      "text": "- Pharma: +9%, highlighted by an improved backdrop for capital spending and high-20% NASD growth",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "a283462f8377e87c",
      "text": "- Dx & Clinical: +4%, led by +HSD growth ex-China in Dako cancer dx",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "64124443c42d398b",
      "text": "- Food: +7%, driven by favorable regulatory initiatives in Europe and Asia ex-China",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "452fa5d44157789a",
      "text": "- CAM: +10%, as capital investment in chemicals improved and continued strength in advanced materials on the back of semi fab build-outs",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "1b21760b5390897b",
      "text": "- A&G: +1%, soft instrument spend in the U.S. partially offset by strength in China and resilience in consumables and services",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "ae73b710b07a1bd5",
      "text": "- Environmental & Forensics: (5%), as soft public spend in the U.S. and China was partially offset by PFAS strength ex-U.S.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "00a30487836fe9a3",
      "text": "FIGURE 3.FY'25 &4Q'25 Guidance",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "b351fe5a57bbc315",
      "text": "FY&#x27;25 Guidance ($M at MP)ACTIONUpdatedOLD%Œî vs. OldBloomberg ConsensusBarclays Research%Œî vs. ST&#x27;25 RevenueRAISED&#36;6,910 - &#36;6,930&#36;6,730 - &#36;6,8102.2%&#36;6,788&#36;6,7922.0%Organic Revenue GrowthRAISED4.3%-4.6%2.5%-3.5%145 bps3.3%3.3%118 bpsAdj. EPSNARROWED&#36;5.56 - &#36;5.59&#36;5.54 - &#36;5.61&#36;0.00&#36;5.58&#36;5.58(&#36;0.00)&#x27;4Q25 RevenueABOVE&#36;1,822 - &#36;1,842&#36;1,713 - &#36;1,7934.5%&#36;1,778&#36;1,7793.0%Adj. EPSBELOW&#36;1.57 - &#36;1.6&#36;1.61 - &#36;1.68(&#36;0.06)&#36;1.60&#36;1.59(&#36;0.01)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "a2bafc70d78919cc",
      "text": "Note, 4Q OLD is what was implied upon prior earnings post Source: Company Reports, Bloomberg, Barclays Research",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "64dae3ad89aa47a9",
      "text": "- FX: (0.1%) HW vs. (1.1%) prior- M&A: 2%, vs. +2%-2.2% prior- Operating CF: \\(1.5B - 1.6B\\) maintained- Net interest & Other: \\(26M\\) vs. \\(15M\\) prior- Tax: 12% maintained- Share count: 285M maintained- Dividends: \\(282M\\) maintained- Tariffs: \\(20M\\) net cost",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "accd62feb672c373",
      "text": "- Core: 4.8% - 6%  \n- Pharma: +MSD-HSD  \n- CAM: +HSD  \n- Dx & Clin: +MSD  \n- Food: +MSD  \n- Env. & For.: +LSD  \n- A&G: (MSD)  \n- FX: 20bps TW  \n- M&A: +2.1%",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "3a1024f2a4e24f75",
      "text": "Instrumentation B2B > 1x led by new LC, LC/MS and GC platforms",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "abab698c705da899",
      "text": "- Infinity III LC posted mid-teens growth. Mgmt. noted early adopters are returning for larger follow-ons due to throughput/productivity gains.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "82c1af6d43c96115",
      "text": "- Pro IQ LC/MS launch is exceeding mgmt. expects, winning key pharma accounts and expanding applications across pharma/biopharma.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "aec55b0cd092c823",
      "text": "- 8850 GC is also seeing strong early traction, with performance and sustainability benefits resonating with customers across energy, chemicals, food, and pharma.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "be13e242e15a05be",
      "text": "- Q3 OM at 25.1% was down 230bps yy, including a \\(\\sim 200\\) bps impact from tariffs and associated logistic costs. The remaining negative impact was primarily due to planned downtime at a BIOVECTRA facility for capacity expansion.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "c11f2f599c0c6150",
      "text": "- Tariff impact was \\(\\) 35\\(M in Q3 and mgmt expects a similar impact in Q4. Net impact to FY25 is\\) \\ \\(20M\\) , and full tariff mitigation is on track for FY26.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "90bffc4392cb8686",
      "text": "- Q4 guided to \\(\\sim +230\\) bps sequential OMx primarily via volume leverage, CDMO ramp, and Ignite cost action gains.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "b0dcc913b182a5cd",
      "text": "- Asia ex-China \\(+10\\%\\) , as Food in the region grew mid-20s on increasing safety regs.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "2e0474bd840cfba3",
      "text": "- India \\(+20\\%\\) , with strength across end markets. Notably, the region benefited from strong Infinity III uptake (pharma QA/QC) and increasing semis/EV spend.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "2b187e75d8e5db60",
      "text": "- China \\(+4\\%\\) , with stable conditions and potential stimulus later CY, particularly in applied markets.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "fe53f9a8af137ab2",
      "text": "- Europe \\(+7\\%\\) , including both Pharma & Food +DD, and CAM and A&G HSD",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "c5b77113fca2ecae",
      "text": "- Americas \\(+5\\%\\) with improved capital spending behavior, led by small-mol pharma and CAM at +LDD. However, biopharma and A&G spend remains softer.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "0294962da05c52f3",
      "text": "- Value-driven pricing impact in Q3 was \\(\\sim 2\\times\\) yy ( \\(\\sim 100\\) bps vs \\(\\sim 50\\) bps in the prior year).",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "b0a4d824f6dffc9b",
      "text": "- Mgmt layers reduced \\(\\sim 15\\%\\) , lowering costs and improving speed",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "6096bcf0ab29b234",
      "text": "- Improving enterprise manufacturing/procurement models have already delivered DD savings in key cost buckets, with more upside as strategy scales globally",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "cfd5100c5327912b",
      "text": "- Tariff task force re-routes supply, shifts production, and deploys targeted pricing - helping fully mitigate tariffs in FY26 at current rates.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "212fc98553cd2c28",
      "text": "- PFAS grew LDD globally while facing a \\(\\sim 50\\%\\) comp last year, driven by ex-U.S. demand at +low-30s growth in the Q",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "2912dc61fff1445a",
      "text": "- Americas PFAS down \\(\\sim 20\\%\\) on EPA-related capital uncertainty, but mgmt doesn't see change to LT testing demand.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "775b94ab95f70a78",
      "text": "- NT U.S. PFAS capex cautious into Q4/Q1",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "ea74ca450d004ab0",
      "text": "I, Luke Sergott, hereby certify (1) that the views expressed in this research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "ac4240b09c1eaf9d",
      "text": "Agilent (A, 27- Aug- 2025, USD 118.69), Equal Weight/Neutral, A/CD/CE/D/E/J/K/L/M",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "4f05449333136116",
      "text": "Unless otherwise indicated, prices are sourced from Bloomberg and reflect the closing price in the relevant trading market, which may not be the last available closing price at the time of publication.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "d693b7019a25e897",
      "text": "P: A partner, director or officer of Barclays Capital Canada Inc. has, during the preceding 12 months, provided services to the subject company for remuneration, other than normal course investment advisory or trade execution services.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "38f65d6fa0945d66",
      "text": "R: Barclays Capital Canada Inc. has received compensation for investment banking services from this issuer in the past 12 months.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "d5ba8d7126d6c88d",
      "text": "S: This issuer is a Corporate Broker to Barclays PLC.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "5b81bc3929649fcf",
      "text": "U: The equity securities of this Canadian issuer include subordinate voting restricted shares.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "86cee0042e015066",
      "text": "V: The equity securities of this Canadian issuer include non- voting restricted shares.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "3ad02f6a89745bdb",
      "text": "Overweight - The stock is expected to outperform the unweighted expected total return of the industry coverage universe over a 12- month investment horizon.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "2d747f1132ceccbe",
      "text": "Equal Weight - The stock is expected to perform in line with the unweighted expected total return of the industry coverage universe over a 12- month investment horizon.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "84d39b0d8c538b3d",
      "text": "Underweight - The stock is expected to underperform the unweighted expected total return of the industry coverage universe over a 12- month investment horizon.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "f665a9a9690f91fd",
      "text": "Positive - industry coverage universe fundamentals/valuations are improving.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "27759510e3a33472",
      "text": "Neutral - industry coverage universe fundamentals/valuations are steady, neither improving nor deteriorating.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "eb6ec2e1b52fb59d",
      "text": "Negative - industry coverage universe fundamentals/valuations are deteriorating.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "de6dd3534ee410f6",
      "text": "Below is the list of companies that constitute the \"industry coverage universe\":",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "c37d76307ead4623",
      "text": "10X Genomics (TXG) Bruker (BRKR) Danaher Corp. (DHR) Guardant Health (GH) IQVIA (IQV)",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "014a4e9b60a4acf0",
      "text": "Agilent (A) Certara (CERT) Exact Sciences (EXAS) ICON (ICLR) Labcorp (LH)",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "4ce908978e31b5d1",
      "text": "Avantor (AVTR) Charles River Labs (CRL) Fortrea (FTRE) Illumina Inc. (ILMN) Medpace (MEDP)",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "b0fb00e2d42e9c73",
      "text": "Mettler Toledo International Inc. (MTD) QIAGEN (QGEN) Revvity (RVTY) Twist Bioscience (TWST)",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "343c43e89a2d31ca",
      "text": "Natera (NTRA) Quest Diagnostics (DGX) Sotera Health Company (SHC) Waters Corporation (WAT)",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "2f6a42459175dc6e",
      "text": "Pacbio (PACB) Repligen (RGEN) Thermo Fisher Scientific (TMO) West Pharma Services (WST)",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "4565b1be9263399e",
      "text": "In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts within Equity Research. Any such investment recommendations shall remain open until they are subsequently amended, rebalanced or closed in a future research report.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "9da51cbdb27eacfe",
      "text": "Barclays may also re- distribute equity research reports produced by third- party research providers that contain recommendations that differ from and/or conflict with those published by Barclays' Equity Research Department.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "107bfcb392282ab3",
      "text": "Barclays Equity Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays Equity Research in the preceding 12 months please refer to https://live.barcap.com/go/research/Recommendations.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "05858d90158c587d",
      "text": "Stock Rating: EQUAL WEIGHTIndustry View: NEUTRALClosing Price: USD 118.69 (27-Aug-2025)",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "37993c3196e8f369",
      "text": "Rating and Price Target Chart - USD (as of 27-Aug-2025)Currency=USD",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "4ca9c24bdd71ae9f",
      "text": "Source: IDC, Barclays Research",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "07c638f31b98d475",
      "text": "Link to Barclays Live for interactive charting",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "b86d8828cf07e5a2",
      "text": "Publication DateClosing Price*RatingAdjusted Price Target24-Jun-2025115.56125.0010-Apr-2025107.05115.0027-Feb-2025134.47138.0010-Feb-2025145.21Equal Weight145.0026-Nov-2024134.49135.0015-Oct-2024144.25145.0022-Aug-2024139.99135.0030-May-2024145.48125.0009-Apr-2024144.46135.0027-Feb-2024132.55125.0024-Jan-2024131.64120.0021-Nov-2023113.98100.0028-Sep-2023110.50105.0015-Aug-2023126.65Underweight110.0031-Jul-2023126.05115.0026-Jun-2023118.68130.0024-May-2023128.64135.0011-May-2023127.35Equal Weight140.00",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "77833eca632e950f",
      "text": "Source: Bloomberg, Barclays Research",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "e16d2de19dcc4fec",
      "text": "\\*This is the closing price referenced in the publication, which may not be the last available closing price at the time of publication.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "668acb5f0eac37c9",
      "text": "Historical stock prices and price targets may have been adjusted for stock splits and dividends.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "002b52f03aa3bf37",
      "text": "Valuation Methodology: Our \\(\\) 125\\(PT applies a 21x multiple to our FY'26 EPS estimate of\\) \\ \\(6.06\\)",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "296e7f04b8fa5844",
      "text": "Risks which May Impede the Achievement of the Barclays Research Valuation and Price Target: Risks to the upside include the following: 1) macro and funding fears ease sooner than expected, customers increase spending; 2) demand for PFAS testing solutions increases faster than expected and other nations come forward with increased regulation; 3) instrument demand does not ease and management continues to realize outsized pricing. Downside risks include: 1) macro uncertainty causes capex spending to take a step back; 2) NASD slower ramp and utilization than expected; 3) China backdrop deteriorates further.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "aa0be7dafabb479f",
      "text": "purposes of the UK Alternative Investment Fund Managers Regulations 2013 (SI 2013/1773) or AIFMD (Directive 2011/61)) or pre- marketing (including, without limitation, for the purposes of Directive (EU) 2019/1160) of the securities, products or issuers that are the subject of this report.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "7609de93a5456c7d",
      "text": "Third Party Distribution: Any views expressed in this communication are solely those of Barclays and have not been adopted or endorsed by any third party distributor.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "a35c683f7644505f",
      "text": "This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of Canadian Investment Regulatory Organization (www.ciro.ca), and a Member of the Canadian Investor Protection Fund (CIPF).",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "edff2d36f0dcd2f7",
      "text": "This communication is directed at persons who are a \"Wholesale Client\" as defined by the Australian Corporations Act 2001.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "1ddb51aaf85e27b7",
      "text": "Middle East: Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 (\"Advisory Law\"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "665c7ee15f08d147",
      "text": "Russia: This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non- Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "51938021c0f55735",
      "text": "Sustainable Investing Related Research: There is currently no globally accepted framework or definition (legal, regulatory or otherwise) of, nor market consensus as to what constitutes a 'sustainable', 'ESG', 'green', 'climate- friendly' or an equivalent company, investment, strategy or consideration or what precise attributes are required to be eligible to be categorised by such terms. This means there are different ways to evaluate a company or an investment and so different values may be placed on certain sustainability credentials as well as adverse ESG- related impacts of companies and ESG controversies. The evolving nature of sustainable investing considerations, models and methodologies means it can be challenging to definitively and universally classify a company or investment under a sustainable investing label and there may be areas where such companies and investments could improve or where adverse ESG- related impacts or ESG controversies exist. The evolving nature of sustainable finance related regulations and the development of jurisdiction- specific regulatory criteria also means that there is likely to be a degree of divergence as to the interpretation of such terms in the market. We expect industry guidance, market practice, and regulations in this field to continue to evolve.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "e1e91382da9a9ac5",
      "text": "Any information, data, image, or other content including from a third party source contained, referred to herein or used for whatsoever purpose by Barclays or a third party (\"Information\"), in relation to any actual or potential 'ESG', 'sustainable' or equivalent objective, issue, factor or consideration is not intended to be relied upon for ESG or sustainability classification, regulatory regime or industry initiative purposes (\"ESG Regimes\"), unless otherwise stated. Nothing in these materials, including any images included therein, is intended to convey, suggest or indicate that Barclays considers or represents any product, service, person or body mentioned in these materials as meeting or qualifying for any ESG or sustainability classification, label or similar standards that may exist under ESG Regimes. Barclays has not conducted any assessment of compliance with ESG Regimes. Parties are reminded to make their own assessments for these purposes.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "e973622d622edc6d",
      "text": "IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax- related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.",
      "page": 14,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "8ecf5f701f73bde6",
      "name": "Adjusted Price",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d1cf412485ca8530",
      "name": "Advisory Law",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7fb30d78cc02b3f7",
      "name": "Americas PFAS",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "3f19bf164f69ace0",
      "name": "Annual EPS",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "facedae141187a9f",
      "name": "Australian Corporations",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "46a2e39eafb9f3ae",
      "name": "Barclays Capital",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "64387d09d2494c79",
      "name": "Barclays Capital Canada Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4d2d57430a6b5e51",
      "name": "Barclays Equity",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d1d3bfaf58595d0a",
      "name": "Barclays Israeli",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "05ab2ec667d770bf",
      "name": "Barclays Live",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "520bb613ae942fa6",
      "name": "Barclays PLC",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ccf133d649c357ba",
      "name": "Barclays Research",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "3ec0ba704b7d9bd6",
      "name": "Bloomberg\n\nPrice",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8237fc9549728c51",
      "name": "Bloomberg Consensus",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "5bfee5aaab89f6d4",
      "name": "Call\n\nInstrumentation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "13eec11f9f77d58d",
      "name": "Canada Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d704b6ac0c024d24",
      "name": "Canadian Investor",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ea665dd75efb68b2",
      "name": "Charles River",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "3d9e178724d263f9",
      "name": "Closing Price",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "0e24bee8bdf65177",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "se heightened expectations, especially in Crosslab and AMG. Notably, the CAM end market was strong (+10%) as a GC instrument replacement cycle seemed to begin/meaningfully accelerate and semi fab buil",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1f0c3226ca260fc6",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "gin/meaningfully accelerate and semi fab build- outs continued. This replacement cycle for GC- MS (~20% of the biz) has a longer conversion rate, so we can expect this to be a more drawn out TW for th",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "6cd1ad3bb8975deb",
        "value": 0.053,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "U.S. Life Science & Diagnostic Tools Price Target Price (27- Aug- 25) Potential Upside/Downside +5.3% Source: Bloomberg, Barclays Research Market Cap (USD mn) 33715 Shares Outstanding (mn) 284.06 Free",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "97aecba6f45e34cd",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>1.29A</td><td>1.31A</td><td>1.31A</td><td>1.31A</td><td>N/A</td><td>1.46E</td><td>1.43E</td><td>2%</td><td>11%</td><td></td></tr><tr><td>Q2</td><td>1.22A</td><td>1.31A</td><td>1.31A</td><td>1.31A<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "448fa8a6f6f8de04",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>1.31A</td><td>1.31A</td><td>1.31A</td><td>N/A</td><td>1.46E</td><td>1.43E</td><td>2%</td><td>11%</td><td></td></tr><tr><td>Q2</td><td>1.22A</td><td>1.31A</td><td>1.31A</td><td>1.31A</td><td>N/A",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "00bc55be25801115",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>1.22A</td><td>1.31A</td><td>1.31A</td><td>1.31A</td><td>N/A</td><td>1.46E</td><td>1.43E</td><td>7%</td><td>11%</td><td></td></tr><tr><td>Q3</td><td>1.32A</td><td>1.37E</td><td>1.37A</td><td>1.37E<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "448fa8a6f6f8de04",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>1.31A</td><td>1.31A</td><td>1.31A</td><td>N/A</td><td>1.46E</td><td>1.43E</td><td>7%</td><td>11%</td><td></td></tr><tr><td>Q3</td><td>1.32A</td><td>1.37E</td><td>1.37A</td><td>1.37E</td><td>N/A",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "b5716a7a8091ef5f",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>1.32A</td><td>1.37E</td><td>1.37A</td><td>1.37E</td><td>N/A</td><td>1.51E</td><td>1.51E</td><td>4%</td><td>10%</td><td></td></tr><tr><td>Q4</td><td>1.46A</td><td>1.59E</td><td>1.58E</td><td>1.60E<",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "0d00c5bfc9ae94b8",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>1.37E</td><td>1.37A</td><td>1.37E</td><td>N/A</td><td>1.51E</td><td>1.51E</td><td>4%</td><td>10%</td><td></td></tr><tr><td>Q4</td><td>1.46A</td><td>1.59E</td><td>1.58E</td><td>1.60E</td><td>N/A",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "50201638193d5544",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>1.46A</td><td>1.59E</td><td>1.58E</td><td>1.60E</td><td>N/A</td><td>1.64E</td><td>1.70E</td><td>8%</td><td>4%</td><td></td></tr><tr><td>Year</td><td>5.28A</td><td>5.58E</td><td>5.57E</td><td>5.58E",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a94043a839687700",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>1.59E</td><td>1.58E</td><td>1.60E</td><td>N/A</td><td>1.64E</td><td>1.70E</td><td>8%</td><td>4%</td><td></td></tr><tr><td>Year</td><td>5.28A</td><td>5.58E</td><td>5.57E</td><td>5.58E</td><td>6.",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "15ed48015911d6b9",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>5.28A</td><td>5.58E</td><td>5.57E</td><td>5.58E</td><td>6.01E</td><td>6.06E</td><td>6.05E</td><td>5%</td><td>9%</td><td></td></tr><tr><td>P/E</td><td>22.5</td><td></td><td>21.3</td><td></td><td></td",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "ecb7aa8787aca7a2",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>5.58E</td><td>5.57E</td><td>5.58E</td><td>6.01E</td><td>6.06E</td><td>6.05E</td><td>5%</td><td>9%</td><td></td></tr><tr><td>P/E</td><td>22.5</td><td></td><td>21.3</td><td></td><td></td><td>19.6</",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "e4ba78f0b9a2b0cc",
        "value": 0.055999999999999994,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "UAL WEIGHT</td></tr><tr><td>Revenue</td><td>6,510</td><td>6,918</td><td>7,258</td><td>7,665</td><td>5.6%</td><td>Price Target USD 118.69</td></tr><tr><td>EBITDA (adj)</td><td>1,875</td><td>1,961</td><",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "78d366e3ba80d9ce",
        "value": 0.066,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "18.69</td></tr><tr><td>EBITDA (adj)</td><td>1,875</td><td>1,961</td><td>2,080</td><td>2,269</td><td>6.6%</td><td>Price Target USD 125.00</td></tr><tr><td>EBIT (adj)</td><td>1,720</td><td>1,780</td><td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "abd84e51bb1d78a2",
        "value": 0.071,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "125.00</td></tr><tr><td>EBIT (adj)</td><td>1,720</td><td>1,780</td><td>1,935</td><td>2,115</td><td>7.1%</td><td>Why EQUAL WEIGHT?</td></tr><tr><td>Pre-tax income (adj)</td><td>1,755</td><td>1,806</td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "f5a99b953a249f8a",
        "value": 0.061,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Pre-tax income (adj)</td><td>1,755</td><td>1,806</td><td>1,935</td><td>2,095</td><td>6.1%</td><td>We expect Agilent to maintain its HSD topline/LDD EPS compounding</td></tr><tr><td>Net ",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "6ef340114007b560",
        "value": 0.062,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "g</td></tr><tr><td>Net income (adj)</td><td>1,538</td><td>1,589</td><td>1,703</td><td>1,844</td><td>6.2%</td><td>algo over time by capturing secular TWs. We remain on the sidelines</td></tr><tr><td>EP",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "a89e547dd3a2edaf",
        "value": 0.077,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "elines</td></tr><tr><td>EPS (adj) (US$)</td><td>5.28</td><td>5.57</td><td>6.06</td><td>6.59</td><td>7.7%</td><td>given elevated valuations as the instrumentation recovery is underway, but we remain ca",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "8e68f53029ea27d6",
        "value": -0.013000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "itics.</td></tr><tr><td>Diluted shares (mn)</td><td>291</td><td>284</td><td>281</td><td>280</td><td>-1.3%</td><td></td></tr><tr><td>DPS (US$)</td><td>0.94</td><td>1.00</td><td>1.04</td><td>1.08</td><t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "bfaf13bcf7d7d74a",
        "value": 0.046,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".3%</td><td></td></tr><tr><td>DPS (US$)</td><td>0.94</td><td>1.00</td><td>1.04</td><td>1.08</td><td>4.6%</td><td></td></tr><tr><td>Margin and return data</td><td>2024A</td><td>2025E</td><td>2026E</td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "cad0368a08a44403",
        "value": 0.102,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>Tangible fixed assets</td><td>1,778</td><td>2,046</td><td>2,264</td><td>2,379</td><td>10.2%</td><td>Downside is driven by Agilent catching more secular tailwinds than anticipated and the",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "3c6fa7d026cd5b57",
        "value": 0.033,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td>Intangible fixed assets</td><td>5,024</td><td>5,839</td><td>5,694</td><td>5,540</td><td>3.3%</td><td></td></tr><tr><td>Cash and equivalents</td><td>1,329</td><td>1,194</td><td>1,374</td><t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "c5e580a5e14e935c",
        "value": 0.079,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Cash and equivalents</td><td>1,329</td><td>1,194</td><td>1,374</td><td>1,671</td><td>7.9%</td><td></td></tr><tr><td>Total assets</td><td>11,846</td><td>12,608</td><td>13,005</td><td>13,",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "852f224b96ef5a4d",
        "value": 0.043,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td></tr><tr><td>Total assets</td><td>11,846</td><td>12,608</td><td>13,005</td><td>13,431</td><td>4.3%</td><td></td></tr><tr><td>Short and long-term debt</td><td>3,345</td><td>3,345</td><td>3,046</t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "c43957dbc57c8123",
        "value": -0.099,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><tr><td>Short and long-term debt</td><td>3,345</td><td>3,345</td><td>3,046</td><td>2,450</td><td>-9.9%</td><td></td></tr><tr><td>Other long-term liabilities</td><td>708</td><td>692</td><td>653</td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "39357ec1e2442edf",
        "value": -0.009000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>Other long-term liabilities</td><td>708</td><td>692</td><td>653</td><td>690</td><td>-0.9%</td><td></td></tr><tr><td>Total liabilities</td><td>5,948</td><td>5,988</td><td>5,619</td><td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "30fcb2a7b4b8cb08",
        "value": -0.046,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>Total liabilities</td><td>5,948</td><td>5,988</td><td>5,619</td><td>5,157</td><td>-4.6%</td><td></td></tr><tr><td>Net debt/(funds)</td><td>2,016</td><td>2,151</td><td>1,672</td><td>7",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "bc599702354acdc2",
        "value": -0.272,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td></tr><tr><td>Net debt/(funds)</td><td>2,016</td><td>2,151</td><td>1,672</td><td>779</td><td>-27.2%</td><td></td></tr><tr><td>Shareholders' equity</td><td>5,898</td><td>6,620</td><td>7,385</td>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "cca87fdf70036e6d",
        "value": 0.11900000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d></tr><tr><td>Shareholders' equity</td><td>5,898</td><td>6,620</td><td>7,385</td><td>8,275</td><td>11.9%</td><td></td></tr><tr><td>Change in working capital</td><td>83</td><td>59</td><td>-128</td><td",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "26ddadab51b5009e",
        "value": 0.039,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>Cash flow from operations</td><td>1,751</td><td>2,000</td><td>1,637</td><td>1,965</td><td>3.9%</td><td></td></tr><tr><td>Capital expenditure</td><td>-378</td><td>-450</td><td>-363</td><td>-2",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "92484ab403559379",
        "value": 0.073,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td></tr><tr><td>Free cash flow</td><td>1,373</td><td>1,550</td><td>1,275</td><td>1,696</td><td>7.3%</td><td></td></tr><tr><td>Valuation and leverage metrics</td><td>2024A</td><td>2025E</td><td>20",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "bd9a12f670585463",
        "value": 0.043,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Barclays Research</td></tr><tr><td>Total Revenue</td><td>BEAT</td><td>$1,738</td><td>$1,666</td><td>4.3%</td><td>$1,664</td></tr><tr><td>Core</td><td>BEAT</td><td>6.1%</td><td>2.9%</td><td>320 bps</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "927c2c400a70f8e3",
        "value": 0.061,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>$1,738</td><td>$1,666</td><td>4.3%</td><td>$1,664</td></tr><tr><td>Core</td><td>BEAT</td><td>6.1%</td><td>2.9%</td><td>320 bps</td><td>2.9%</td></tr><tr><td>Adj. OM</td><td>MISSED</td><td>25.1%",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "e0436440a1668463",
        "value": 0.028999999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>$1,666</td><td>4.3%</td><td>$1,664</td></tr><tr><td>Core</td><td>BEAT</td><td>6.1%</td><td>2.9%</td><td>320 bps</td><td>2.9%</td></tr><tr><td>Adj. OM</td><td>MISSED</td><td>25.1%</td><td>26.6",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "8cbfb6f5c974a89b",
        "value": 0.028999999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>$1,664</td></tr><tr><td>Core</td><td>BEAT</td><td>6.1%</td><td>2.9%</td><td>320 bps</td><td>2.9%</td></tr><tr><td>Adj. OM</td><td>MISSED</td><td>25.1%</td><td>26.6%</td><td>(141 bps)</td><td>2",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "7cf4fb3dc0cc1eb3",
        "value": 0.251,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>6.1%</td><td>2.9%</td><td>320 bps</td><td>2.9%</td></tr><tr><td>Adj. OM</td><td>MISSED</td><td>25.1%</td><td>26.6%</td><td>(141 bps)</td><td>26.3%</td></tr><tr><td>Adj. EPS</td><td>IN-LINE</td><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "c02e24d07500e89b",
        "value": 0.266,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>2.9%</td><td>320 bps</td><td>2.9%</td></tr><tr><td>Adj. OM</td><td>MISSED</td><td>25.1%</td><td>26.6%</td><td>(141 bps)</td><td>26.3%</td></tr><tr><td>Adj. EPS</td><td>IN-LINE</td><td>$1.37</td><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "c36e321f1bf042a0",
        "value": 0.263,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">2.9%</td></tr><tr><td>Adj. OM</td><td>MISSED</td><td>25.1%</td><td>26.6%</td><td>(141 bps)</td><td>26.3%</td></tr><tr><td>Adj. EPS</td><td>IN-LINE</td><td>$1.37</td><td>$1.37</td><td>$0.00</td><td>$1",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "984a73b1fc449fe5",
        "value": 0.045,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td></td><td></td><td></td></tr><tr><td>Revenue</td><td>BEAT</td><td>$670</td><td>$641</td><td>4.5%</td></tr><tr><td>Core*</td><td>BEAT</td><td>7.0%</td><td>3.0%</td><td>400 bps</td></tr><tr><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "a41bb6edcb2be02d",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nue</td><td>BEAT</td><td>$670</td><td>$641</td><td>4.5%</td></tr><tr><td>Core*</td><td>BEAT</td><td>7.0%</td><td>3.0%</td><td>400 bps</td></tr><tr><td>OM</td><td>MISSED</td><td>17.6%</td><td>21.5%</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f3d7d6040814f3de",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "EAT</td><td>$670</td><td>$641</td><td>4.5%</td></tr><tr><td>Core*</td><td>BEAT</td><td>7.0%</td><td>3.0%</td><td>400 bps</td></tr><tr><td>OM</td><td>MISSED</td><td>17.6%</td><td>21.5%</td><td>(386 bps",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "26988b25afad40c5",
        "value": 0.17600000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "*</td><td>BEAT</td><td>7.0%</td><td>3.0%</td><td>400 bps</td></tr><tr><td>OM</td><td>MISSED</td><td>17.6%</td><td>21.5%</td><td>(386 bps)</td></tr><tr><td>ACG</td><td></td><td></td><td></td><td></td><",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "4a9fc30c11fce320",
        "value": 0.215,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>7.0%</td><td>3.0%</td><td>400 bps</td></tr><tr><td>OM</td><td>MISSED</td><td>17.6%</td><td>21.5%</td><td>(386 bps)</td></tr><tr><td>ACG</td><td></td><td></td><td></td><td></td></tr><tr><td>Re",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "596ee3d94542a99e",
        "value": 0.037000000000000005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td></td><td></td><td></td></tr><tr><td>Revenue</td><td>BEAT</td><td>$744</td><td>$717</td><td>3.7%</td></tr><tr><td>Core</td><td>BEAT</td><td>5.0%</td><td>2.7%</td><td>235 bps</td></tr><tr><td>O",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f00c7e257fe10d50",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "enue</td><td>BEAT</td><td>$744</td><td>$717</td><td>3.7%</td></tr><tr><td>Core</td><td>BEAT</td><td>5.0%</td><td>2.7%</td><td>235 bps</td></tr><tr><td>OM</td><td>BEAT</td><td>33.3%</td><td>32.4%</td><",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "18842661cff5713a",
        "value": 0.027000000000000003,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "BEAT</td><td>$744</td><td>$717</td><td>3.7%</td></tr><tr><td>Core</td><td>BEAT</td><td>5.0%</td><td>2.7%</td><td>235 bps</td></tr><tr><td>OM</td><td>BEAT</td><td>33.3%</td><td>32.4%</td><td>91 bps</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "a9355c954642c156",
        "value": 0.33299999999999996,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ore</td><td>BEAT</td><td>5.0%</td><td>2.7%</td><td>235 bps</td></tr><tr><td>OM</td><td>BEAT</td><td>33.3%</td><td>32.4%</td><td>91 bps</td></tr><tr><td>AMG</td><td></td><td></td><td></td><td></td></tr",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "019ea1f55fd226b3",
        "value": 0.324,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "AT</td><td>5.0%</td><td>2.7%</td><td>235 bps</td></tr><tr><td>OM</td><td>BEAT</td><td>33.3%</td><td>32.4%</td><td>91 bps</td></tr><tr><td>AMG</td><td></td><td></td><td></td><td></td></tr><tr><td>Reven",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "b9bab2116c2f6de1",
        "value": 0.053,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td></td><td></td><td></td></tr><tr><td>Revenue</td><td>BEAT</td><td>$324</td><td>$308</td><td>5.3%</td></tr><tr><td>Core*</td><td>BEAT</td><td>5.0%</td><td>1.0%</td><td>400 bps</td></tr><tr><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "c35db1375b8c7bf3",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "nue</td><td>BEAT</td><td>$324</td><td>$308</td><td>5.3%</td></tr><tr><td>Core*</td><td>BEAT</td><td>5.0%</td><td>1.0%</td><td>400 bps</td></tr><tr><td>OM</td><td>MISSED</td><td>21.8%</td><td>23.5%</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f64e2da88b9dbaa2",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "EAT</td><td>$324</td><td>$308</td><td>5.3%</td></tr><tr><td>Core*</td><td>BEAT</td><td>5.0%</td><td>1.0%</td><td>400 bps</td></tr><tr><td>OM</td><td>MISSED</td><td>21.8%</td><td>23.5%</td><td>(174 bps",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "cfe1644b46ceb328",
        "value": 0.218,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "*</td><td>BEAT</td><td>5.0%</td><td>1.0%</td><td>400 bps</td></tr><tr><td>OM</td><td>MISSED</td><td>21.8%</td><td>23.5%</td><td>(174 bps)</td></tr></table> LDG & AMG core growth variance reflects Barc",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "88813a7d92dfc5a0",
        "value": 0.235,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>5.0%</td><td>1.0%</td><td>400 bps</td></tr><tr><td>OM</td><td>MISSED</td><td>21.8%</td><td>23.5%</td><td>(174 bps)</td></tr></table> LDG & AMG core growth variance reflects Barclays estimates",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "c6368e7277bb3db6",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Barclays estimates Source: Company Reports, Bloomberg, Barclays Research ## End-Markets - Pharma: +9%, highlighted by an improved backdrop for capital spending and high-20% NASD growth - Dx & Clinical",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "7b1e25fb66c6ce8a",
        "value": -0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ch ## End-Markets - Pharma: +9%, highlighted by an improved backdrop for capital spending and high-20% NASD growth - Dx & Clinical: +4%, led by +HSD growth ex-China in Dako cancer dx - Food: +7%, driv",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "fdae84ffead6abff",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "highlighted by an improved backdrop for capital spending and high-20% NASD growth - Dx & Clinical: +4%, led by +HSD growth ex-China in Dako cancer dx - Food: +7%, driven by favorable regulatory initia",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "abbdde002d8dfba1",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "high-20% NASD growth - Dx & Clinical: +4%, led by +HSD growth ex-China in Dako cancer dx - Food: +7%, driven by favorable regulatory initiatives in Europe and Asia ex-China - CAM: +10%, as capital in",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "88c1c29ef634f4cf",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "cer dx - Food: +7%, driven by favorable regulatory initiatives in Europe and Asia ex-China - CAM: +10%, as capital investment in chemicals improved and continued strength in advanced materials on the ",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "c38e62f50e40207d",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ls improved and continued strength in advanced materials on the back of semi fab build-outs - A&G: +1%, soft instrument spend in the U.S. partially offset by strength in China and resilience in consum",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "96db52ad4b4e893e",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "fset by strength in China and resilience in consumables and services - Environmental & Forensics: (5%), as soft public spend in the U.S. and China was partially offset by PFAS strength ex-U.S.<ÔΩúend‚ñÅof",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f3240622d2035de3",
        "value": 1738.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "3Q&#x27;25</td><td>%Œî</td><td>Barclays Research</td></tr><tr><td>Total Revenue</td><td>BEAT</td><td>$1,738</td><td>$1,666</td><td>4.3%</td><td>$1,664</td></tr><tr><td>Core</td><td>BEAT</td><td>6.1%</t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "5e52156794e04452",
        "value": 1666.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td>%Œî</td><td>Barclays Research</td></tr><tr><td>Total Revenue</td><td>BEAT</td><td>$1,738</td><td>$1,666</td><td>4.3%</td><td>$1,664</td></tr><tr><td>Core</td><td>BEAT</td><td>6.1%</td><td>2.9%</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "9d7a181052967a40",
        "value": 1664.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "arch</td></tr><tr><td>Total Revenue</td><td>BEAT</td><td>$1,738</td><td>$1,666</td><td>4.3%</td><td>$1,664</td></tr><tr><td>Core</td><td>BEAT</td><td>6.1%</td><td>2.9%</td><td>320 bps</td><td>2.9%</td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "83973f30b46b742a",
        "value": 1.37,
        "unit": "$",
        "metric_type": "currency",
        "context": ".1%</td><td>26.6%</td><td>(141 bps)</td><td>26.3%</td></tr><tr><td>Adj. EPS</td><td>IN-LINE</td><td>$1.37</td><td>$1.37</td><td>$0.00</td><td>$1.37</td></tr></table> Source: Company Reports, Bloomberg",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "c11082e89f4993b1",
        "value": 1.37,
        "unit": "$",
        "metric_type": "currency",
        "context": ".6%</td><td>(141 bps)</td><td>26.3%</td></tr><tr><td>Adj. EPS</td><td>IN-LINE</td><td>$1.37</td><td>$1.37</td><td>$0.00</td><td>$1.37</td></tr></table> Source: Company Reports, Bloomberg, Barclays Res",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f4b874194fc4868d",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "41 bps)</td><td>26.3%</td></tr><tr><td>Adj. EPS</td><td>IN-LINE</td><td>$1.37</td><td>$1.37</td><td>$0.00</td><td>$1.37</td></tr></table> Source: Company Reports, Bloomberg, Barclays Research FIGURE 2",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "54643ccaa6cd6123",
        "value": 1.37,
        "unit": "$",
        "metric_type": "currency",
        "context": "d>26.3%</td></tr><tr><td>Adj. EPS</td><td>IN-LINE</td><td>$1.37</td><td>$1.37</td><td>$0.00</td><td>$1.37</td></tr></table> Source: Company Reports, Bloomberg, Barclays Research FIGURE 2.3Q'25 Segment",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "00106704ce67cd77",
        "value": 670.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "></tr><tr><td>LDG</td><td></td><td></td><td></td><td></td></tr><tr><td>Revenue</td><td>BEAT</td><td>$670</td><td>$641</td><td>4.5%</td></tr><tr><td>Core*</td><td>BEAT</td><td>7.0%</td><td>3.0%</td><td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "7beab0d49bb75f9c",
        "value": 641.0,
        "unit": "$",
        "metric_type": "currency",
        "context": ">LDG</td><td></td><td></td><td></td><td></td></tr><tr><td>Revenue</td><td>BEAT</td><td>$670</td><td>$641</td><td>4.5%</td></tr><tr><td>Core*</td><td>BEAT</td><td>7.0%</td><td>3.0%</td><td>400 bps</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "b6eb547d22e445ff",
        "value": 744.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "></tr><tr><td>ACG</td><td></td><td></td><td></td><td></td></tr><tr><td>Revenue</td><td>BEAT</td><td>$744</td><td>$717</td><td>3.7%</td></tr><tr><td>Core</td><td>BEAT</td><td>5.0%</td><td>2.7%</td><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f2fb960de560f62e",
        "value": 717.0,
        "unit": "$",
        "metric_type": "currency",
        "context": ">ACG</td><td></td><td></td><td></td><td></td></tr><tr><td>Revenue</td><td>BEAT</td><td>$744</td><td>$717</td><td>3.7%</td></tr><tr><td>Core</td><td>BEAT</td><td>5.0%</td><td>2.7%</td><td>235 bps</td><",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "86e3fa79168bc151",
        "value": 324.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "></tr><tr><td>AMG</td><td></td><td></td><td></td><td></td></tr><tr><td>Revenue</td><td>BEAT</td><td>$324</td><td>$308</td><td>5.3%</td></tr><tr><td>Core*</td><td>BEAT</td><td>5.0%</td><td>1.0%</td><td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "fda790f01be77ebf",
        "value": 308.0,
        "unit": "$",
        "metric_type": "currency",
        "context": ">AMG</td><td></td><td></td><td></td><td></td></tr><tr><td>Revenue</td><td>BEAT</td><td>$324</td><td>$308</td><td>5.3%</td></tr><tr><td>Core*</td><td>BEAT</td><td>5.0%</td><td>1.0%</td><td>400 bps</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "cbc889542b5036fe",
        "value": 0.022000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "7;25 Revenue</td><td>RAISED</td><td>&#36;6,910 - &#36;6,930</td><td>&#36;6,730 - &#36;6,810</td><td>2.2%</td><td>&#36;6,788</td><td>&#36;6,792</td><td>2.0%</td></tr><tr><td>Organic Revenue Growth</td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "2518fe7154536fe2",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;6,930</td><td>&#36;6,730 - &#36;6,810</td><td>2.2%</td><td>&#36;6,788</td><td>&#36;6,792</td><td>2.0%</td></tr><tr><td>Organic Revenue Growth</td><td>RAISED</td><td>4.3%-4.6%</td><td>2.5%-3.5%</td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "da16f96b25611b3c",
        "value": 0.043,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",788</td><td>&#36;6,792</td><td>2.0%</td></tr><tr><td>Organic Revenue Growth</td><td>RAISED</td><td>4.3%-4.6%</td><td>2.5%-3.5%</td><td>145 bps</td><td>3.3%</td><td>3.3%</td><td>118 bps</td></tr><tr><",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "bfd7d2b8ba757371",
        "value": -0.046,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>&#36;6,792</td><td>2.0%</td></tr><tr><td>Organic Revenue Growth</td><td>RAISED</td><td>4.3%-4.6%</td><td>2.5%-3.5%</td><td>145 bps</td><td>3.3%</td><td>3.3%</td><td>118 bps</td></tr><tr><td>A",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "2d6f4106cef95151",
        "value": 0.025,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6,792</td><td>2.0%</td></tr><tr><td>Organic Revenue Growth</td><td>RAISED</td><td>4.3%-4.6%</td><td>2.5%-3.5%</td><td>145 bps</td><td>3.3%</td><td>3.3%</td><td>118 bps</td></tr><tr><td>Adj. EPS</td><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "012f80925fedf8c2",
        "value": -0.035,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2</td><td>2.0%</td></tr><tr><td>Organic Revenue Growth</td><td>RAISED</td><td>4.3%-4.6%</td><td>2.5%-3.5%</td><td>145 bps</td><td>3.3%</td><td>3.3%</td><td>118 bps</td></tr><tr><td>Adj. EPS</td><td>NA",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "7fbbdbbde33c0af3",
        "value": 0.033,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>Organic Revenue Growth</td><td>RAISED</td><td>4.3%-4.6%</td><td>2.5%-3.5%</td><td>145 bps</td><td>3.3%</td><td>3.3%</td><td>118 bps</td></tr><tr><td>Adj. EPS</td><td>NARROWED</td><td>&#36;5.56 - &#3",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a425b3a539991844",
        "value": 0.033,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "enue Growth</td><td>RAISED</td><td>4.3%-4.6%</td><td>2.5%-3.5%</td><td>145 bps</td><td>3.3%</td><td>3.3%</td><td>118 bps</td></tr><tr><td>Adj. EPS</td><td>NARROWED</td><td>&#36;5.56 - &#36;5.59</td><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "5ffff586f089f19d",
        "value": 0.045,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ";4Q25 Revenue</td><td>ABOVE</td><td>&#36;1,822 - &#36;1,842</td><td>&#36;1,713 - &#36;1,793</td><td>4.5%</td><td>&#36;1,778</td><td>&#36;1,779</td><td>3.0%</td></tr><tr><td>Adj. EPS</td><td>BELOW</td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "810395dbd8d12cd6",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "36;1,842</td><td>&#36;1,713 - &#36;1,793</td><td>4.5%</td><td>&#36;1,778</td><td>&#36;1,779</td><td>3.0%</td></tr><tr><td>Adj. EPS</td><td>BELOW</td><td>&#36;1.57 - &#36;1.6</td><td>&#36;1.61 - &#36;1",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "50e18ab3d0afec29",
        "value": 0.001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "earnings post Source: Company Reports, Bloomberg, Barclays Research ## FY25 Guidance Notes - FX: (0.1%) HW vs. (1.1%) prior- M&A: 2%, vs. +2%-2.2% prior- Operating CF: \\(1.5B - 1.6B\\) maintained- Net ",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "8c374b5440911632",
        "value": 0.011000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Source: Company Reports, Bloomberg, Barclays Research ## FY25 Guidance Notes - FX: (0.1%) HW vs. (1.1%) prior- M&A: 2%, vs. +2%-2.2% prior- Operating CF: \\(1.5B - 1.6B\\) maintained- Net interest & Oth",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "72f96a5ac7f7a172",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ports, Bloomberg, Barclays Research ## FY25 Guidance Notes - FX: (0.1%) HW vs. (1.1%) prior- M&A: 2%, vs. +2%-2.2% prior- Operating CF: \\(1.5B - 1.6B\\) maintained- Net interest & Other: \\(26M\\) vs. \\(",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "02107b0b9046d1b6",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "loomberg, Barclays Research ## FY25 Guidance Notes - FX: (0.1%) HW vs. (1.1%) prior- M&A: 2%, vs. +2%-2.2% prior- Operating CF: \\(1.5B - 1.6B\\) maintained- Net interest & Other: \\(26M\\) vs. \\(15M\\) pr",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "70a2c03565f4368e",
        "value": -0.022000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "mberg, Barclays Research ## FY25 Guidance Notes - FX: (0.1%) HW vs. (1.1%) prior- M&A: 2%, vs. +2%-2.2% prior- Operating CF: \\(1.5B - 1.6B\\) maintained- Net interest & Other: \\(26M\\) vs. \\(15M\\) prior",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "cf5c9014c3d504c1",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "or- Operating CF: \\(1.5B - 1.6B\\) maintained- Net interest & Other: \\(26M\\) vs. \\(15M\\) prior- Tax: 12% maintained- Share count: 285M maintained- Dividends: \\(282M\\) maintained- Tariffs: \\(20M\\) net c",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "875f520bc63d25bd",
        "value": 0.048,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "285M maintained- Dividends: \\(282M\\) maintained- Tariffs: \\(20M\\) net cost ## 4Q Guidance - Core: 4.8% - 6% - Pharma: +MSD-HSD - CAM: +HSD - Dx & Clin: +MSD - Food: +MSD - Env. & For.: +LSD",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "f19b6d367d09da7a",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "intained- Dividends: \\(282M\\) maintained- Tariffs: \\(20M\\) net cost ## 4Q Guidance - Core: 4.8% - 6% - Pharma: +MSD-HSD - CAM: +HSD - Dx & Clin: +MSD - Food: +MSD - Env. & For.: +LSD - A&G",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "5c3ba7c4199d9f76",
        "value": 0.021,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "D - Dx & Clin: +MSD - Food: +MSD - Env. & For.: +LSD - A&G: (MSD) - FX: 20bps TW - M&A: +2.1% ## Key Takes from the Call Instrumentation B2B > 1x led by new LC, LC/MS and GC platforms - Infi",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "80a8be5dae1867b1",
        "value": 0.251,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "dipped 230bps yy in 3Q, but expected to jump +230bps into 4Q as tariff drag nears peak - Q3 OM at 25.1% was down 230bps yy, including a \\(\\sim 200\\) bps impact from tariffs and associated logistic cos",
        "provenance": {
          "page": 7
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 0,
      "tables_count": 0,
      "numerical_data_count": 94,
      "passages_count": 97,
      "entities_count": 20
    }
  }
}